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Abstract 
Gene expression is the fundamental level at which the result of various genetic and regulatory 
programs are observable. The measurement of transcriptome-wide gene expression has 
convincingly switched from microarrays to sequencing in a matter of years. RNA sequencing 
(RNA-seq) provides a quantitative and open system for profiling transcriptional outcomes on a 
large scale and therefore facilitates a large diversity of applications, including basic science 
studies, but also agricultural or clinical situations. In the past 10 years or so, much has been 
learned about the characteristics of the RNA-seq datasets as well as the performance of the 
myriad of methods developed. In this review, we give an overall view of the developments in 
RNA-seq data analysis, including experimental design, with an explicit focus on quantification of 
gene expression and statistical approaches for differential expression. We also highlight 
emerging data types, such as single-cell RNA-seq and gene expression profiling using 
long-read technologies. 
 
Abbreviations: 
DE - differential expression / differentially expressed 
DGE - differential gene expression 
DTE - differential transcript expression 
DTU - differential transcript usage 
GLM - generalized linear model 
DS - differential splicing 
LRT - likelihood ratio test 
TPM - transcripts per million 
EM - expectation maximization 
 
SJ - splice junction 
bp - base pairs 
NB - negative binomial 
ML - maximum likelihood  
MM - method of moments 
FDR - false discovery rate 
VB - variational Bayes 
LRTS - long-read transcript sequencing 
APL - approximate profile likelihood  
 
 Introduction: overview of the RNA sequencing assay 
“After that it gets a bit complicated, and there’s all sort of stuff going on in dimensions thirteen to                   
twenty-two that you really wouldn’t want to know about. All you really need to know for the                 
moment is that the universe is a lot more complicated than you might think, even if you start                  
from a position of thinking it’s pretty damn complicated in the first place.” - ​from Mostly Harmless                 
by Douglas Adams 
 
Molecular biologists are using gene expression studies to get a snapshot of the set of RNA                
molecules present in a biological system, which ultimately dictates what cells are doing or are               
capable of. The original RNA sequencing (RNA-seq) protocols, describing the sequencing of            
complementary DNA (cDNA) fragments on a large scale from a population of cells, were              
published over 10 years ago ​[1–5]​. Since then, the system has been optimized for different               
types and qualities of starting material, as well as different research questions, and many              
distinct and mature protocols are available. 
 
 
Figure 1: Overview of the experimental steps in a RNA-seq protocol. The cDNA library is generated from isolated                  
RNA targets, sequenced and the reads are mapped against a reference genome or transcriptome. Downstream               
data analysis depends on the goal of the experiment and can include, among other things, assessing differential                 
expression, variant calling or genome annotation. 
 
A basic overview of the main steps in a standard RNA-seq experiment is given in Figure 1. The                  
first step is the extraction and purification of RNA from a sample of interest followed by an                 
enrichment of target RNAs. Most commonly used is poly(A) capture, to select for polyadenylated              
RNAs, or ribosomal depletion, to deplete ribosomal and transfer RNAs that are highly abundant              
in a cell (approximately 95% of total RNA) ​[6] and are usually not of primary interest ​[7]​. The                  
selected RNAs are then chemically or enzymatically fragmented to molecules of appropriate            
 
 size (e.g., Illumina TruSeq: 300-500 bp). Current dominant systems (e.g., Illumina) only            
sequence DNA; single-stranded target RNAs are thus reverse transcribed to cDNA (first-strand),            
the RNA is degraded and the first-strand cDNA is complemented to a double strand. Adapter               
sequences are either ligated to the 3’ and 5’ end of the double-stranded cDNA or used as                 
primers in the reverse transcription reaction. The final cDNA library consists of cDNA inserts              
flanked by an adapter sequence on each end. In the last step, the cDNA library is amplified by                  
polymerase chain reaction (PCR) using parts of the adapter sequences as primers. 
 
For Illumina sequencing, the library is loaded onto a flow cell where the cDNAs bind to short                 
oligonucleotides complementary to the adapter sequence. Bridge amplification creates dense          
“clonal clusters” of each cDNA loaded ​[8]​. The sequence of each cluster is determined by a                
process called sequencing by synthesis ​[9]​: single-stranded templates are read as the            
complementary strand is generated. A single fluorescently labeled deoxynucleoside         
triphosphate (dNTP) is added in each step. The label acts as a terminator and prevents the                
incorporation of more than one dNTP at the same time. After the fluorescent label has been                
imaged, it is enzymatically cleaved and the next dNTP can bind to the chain. Base calls are                 
inferred directly from the measured fluorescent signal intensity.  
 
 
Figure 2: Ridge plot showing the      
progression of read length, depth     
and sample size in Sequence Read      
Archive (SRA) projects from the     
recount package ​[10]​. The projects     
are separated by the submission     
year of the biosample. (A) Median      
read length of all samples per project       
and year. The color of the ridge       
indicates the library type of the      
project and the black vertical line      
marks the median. There are 787      
single-end and 1008 paired-end    
projects. Each point represents one     
project. (B) Median number of reads      
across all samples per project and      
year. (C) Number of samples in each       
project. 
 
cDNA libraries can be sequenced in one of two modes: single-end or paired-end. In single-end               
mode, only one end of the cDNA insert is sequenced whereas in paired-end mode, both ends                
are sequenced, yielding two reads in opposite orientation, one from each end. 
 
There are protocols for unstranded and stranded RNA-seq ​[11,12]​, where the latter preserves             
information about the coding strand of each fragment, which is useful in compact genomes or               
with expressed RNAs that originate from opposite strands of the same genomic locus. One              
possibility to construct a stranded library is to use dUTPs in the generation of the second strand                 
 
 cDNA and to degrade the dUTP labeled cDNA before PCR amplification ​[13]​. Other protocols              
use alternative adapters to distinguish between 5’ and 3’ ends of the RNA ​[14]​. 
 
RNA-seq has greatly evolved over time, with early experiments having reads around 35bp long              
and modern (Illumina-based) experiments typically employing 50bp (single-end) or 100bp          
(paired-end) reads (Figure 2A). Most RNA-seq experiments comprise between 10 and 100            
million reads, with a trend towards deeper sequencing over time (Figure 2B). The number of               
samples per project remained constant over the years with a median of around 8 samples               
(Figure 2C). Rapid enhancements in sequencing technology have enabled not only longer read             
lengths (e.g., Illumina MiSeq at 250-300bp) and much higher throughput for the same cost, but               
also much lower amounts of required starting material. Meanwhile, third generation           
technologies, such as Pacific Biosciences (PacBio) and Oxford Nanopore Technologies (ONT),           
allow the sequencing of single molecules and have now been used for sequencing full-length              
transcripts on a transcriptome-wide scale ​[15]​. Further developments are summarized below in            
the section ‘Long Read Transcriptome Sequencing’. In addition, ​single cell RNA-seq is a rapidly              
emerging technique that can be used to sequence the sparse transcriptome of individual cells.              
Some of the early developments in this area are captured in the section ‘Single Cell               
Transcriptome Sequencing’. 
 
Figure 3: Cumulative proportion of reads      
amongst the top expressed genes. The X-axis       
orders genes according to the total number of        
reads they attract and the Y-axis displays the        
cumulative fraction of total reads. Each line       
represents a single RNA-seq sample. Counts      
were downloaded from recount2 ​[10] and 50       
samples were randomly selected from Accession      
SRP060416. 
 
 
Design aspects of RNA-seq 
The basics of experimental design apply equally for RNA-seq as they do for other scientific               
experiments (e.g., see ​[16]​). For example, whether the desired experiment is a simple two-group              
design or a full factorial design, considerations towards ​randomizing experimental units to            
treatments and to avoid confounding factors (e.g., via ​blocking over batches) should be             
respected. In an experiment that must be run in multiple batches (e.g., limited number of               
samples per run), it is critical to represent every experimental condition in each batch, so that,                
 
 when comparing conditions, differences within a batch can be averaged over in the statistical              
modeling. 
 
Specific aspects to be considered while designing an RNA-seq experiment include the number             
of replicates and the depth of sequencing. Ultimately in modern genomic experiments, where             
resources (e.g., material from subjects) are scarce and the RNA-seq experiment in itself is a               
hypothesis-generating tool, the first driver of sample size is budget. For better or worse, many               
RNA-seq studies use as few as three replicates per condition (Figure 2C), near to the minimum                
required to do any statistical analysis. 
  
Sample size calculators can compute the required number of samples to achieve a user defined               
power for detecting differential gene expression ​[17–20]​. However, the user must define many             
parameters, such as the expected alignment rate, the desired power, the significance level and              
the log-fold-change of differentially expressed genes. A recent study came to the conclusion             
that the recommended sample sizes vary from tool to tool, even when estimates from pilot data                
are available ​[21]​. Another issue with sample size calculators is that it might not be obvious how                 
to precisely define the outcome: do we want to find as many DE genes as possible? Do we want                   
a certain power for the lowly expressed genes or the highly expressed ones? In many cases,                
RNA-seq experiments are exploratory and thus a means to further experimentation. 
 
Nonetheless, there is a tradeoff between the number of samples and the sequencing depth in               
terms of discovery performance. Increasing the number of reads might seem always beneficial,             
but a large proportion of the reads originate from a small pool of highly expressed genes and,                 
there is effectively no signal saturation. Figure 3 highlights that more than 80% of reads are                
attributed to the 10% most expressed genes, acknowledging that transcript length also plays a              
role ​[22]​. An increased number of reads only marginally increases the coverage of lowly              
expressed genes and therefore the statistical power to detect differential expression (DE) does             
not improve considerably, especially if the experiment already comprises ~10 million reads per             
sample ​[23]​. In most cases, the budget is better spent on replicates. For example, Schurch et al.                 
show that a higher number of replicates is required to identify DE of genes with low fold change                  
and ideally at least 6 replicates per condition should be used ​[24]​. 
 
There are options for additional capture of genes with low expression, but this implies additional               
labor and cost. In targeted RNA-seq (RNA CaptureSeq), specific regions are first captured by              
probes that are complementary to the region of interest and these selected regions are              
prepared and sequenced ​[25,26]​. After capture, the quantitative nature of the assay is             
maintained ​[25]​; such capture is especially useful in degraded samples (e.g., patient material             
stored in paraffin blocks) where the poly(A) tails may not be present. 
RNA-seq applications 
Clearly, the popularity of RNA-seq is driven by its large number of applications. One obvious               
application area is genome annotation. Even the well studied transcriptomes of humans or             
 
 model organisms such as mice, zebrafish or fruit flies are not complete. Thus, transcriptomics is               
used to annotate novel transcriptional events, such as exon skipping, alternative 3’ acceptor or              
5’ donor sites or intron retention and to understand their usage in normal, developmental or               
pathological conditions. Transcriptomic studies identified previously unknown phenomena, such         
as microexons ​[27]​, cryptic exons ​[28]​, “skiptic” exons ​[29]​, circular RNAs ​[30]​, enhancer RNAs              
[31]​, fusion genes ​[32]​ and so-called epi-transcriptomics involving RNA base modifications ​[33]​. 
 
One of the main application areas is that of gene regulation. RNA-seq enables the comparison               
of gene / transcript / exon expression between different tissues, cell types, genotypes,             
stimulation conditions, time points, disease states, growth conditions and so on. Ultimately, the             
goal of such comparisons is to identify the set of genes that ​change in expression, hopefully                
leading to some understanding of the molecular pathways that are used or altered or the               
regulatory components that are utilized.  
 
Gene expression has been employed for the molecular sub-classification of cancer since the             
early days of microarrays ​[34]​. RNA-seq offers this same capacity, but at higher resolution and               
can include, for example, categorization by splicing ​[35]​. Not surprisingly, there is considerable             
interest in using RNA-seq in clinical applications, to augment or corroborate the information that              
genome sequencing gives ​[36,37]​. 
 
Among others, further applications include spatial transcriptomics, where cellular positional          
information is maintained in the preparation of cDNA fragments ​[38]​, host-pathogen interactions            
via “dual RNA-seq”, where the transcriptomes of both host and pathogen are simultaneously             
assayed ​[39]​, the analysis of genetic variation among expressed genes ​[40]​, RNA editing events              
[41]​, characterization of long non-coding RNAs ​[42]​ and meta-transcriptomics ​[43]​. 
 
Despite the many use cases for bulk RNA-seq, there are applications where single cell              
resolution is desired, especially when studying heterogeneous tissues that consist of more than             
one cell type. While bulk RNA-seq can be computationally deconvoluted to estimate the             
composition of cells present ​[44]​, it is not possible to discover new cell types or perform                
cell-type-specific analyses with bulk RNA-seq and thus single cell RNA-seq opens the door to              
new applications. 
Outline 
The focus of this review is on data analysis aspects, with a view towards equipping the reader                 
with an overall view of the computational steps involved (focus on DE), but also shining a light                 
on various statistical and computational challenges and the range of approaches that have been              
proposed to address them. Not surprisingly, the review is largely geared towards Illumina-based             
RNA-seq data on model organisms, as that is the dominant application area. There are already               
excellent reviews for major application or computational areas, such as ​de novo (or             
reference-based) transcriptome assembly ​[45]​, allele-specific expression analyses ​[46]​,        
expression quantitative trait loci mapping ​[47]​, splicing ​[48]​, analysis of gene regulatory            
 
 networks ​[49] or pathway analyses ​[50,51]​. In a large majority of applications, the overarching              
goal is to identify DE, whether that be at the gene, transcript or exon level. The set of DE                   
entities provides a snapshot into the molecular underpinnings of a stimulus, a disease condition,              
a genetic mutation or any other perturbation being interrogated. In most cases, DE is only an                
intermediate (though critical) step to understanding the biological system under study. 
 
The review is organized as follows. First, we discuss ‘Alignment and Quantification’, where             
RNA-seq reads are placed in the context of the genome and/or annotation catalogs and the               
relative expression level of each target is assessed. Following quantification, we split the rather              
broad topic of DE into ‘Basics of differential expression’, which lays the foundation for the               
current frameworks, and ‘Variants of differential expression’, to highlight the diverse conceptual            
tools available to run the discovery process. Following this, we discuss two rapidly evolving              
research areas, namely ‘Single Cell Transcriptome Sequencing’ and ‘Long Read Transcriptome           
Sequencing’, which have both experienced considerable activity in the last few years. 
Alignment and Quantification 
After an experiment has been designed and executed, the analyst is presented with files              
containing potentially millions to billions of short cDNA fragments. Following sufficient quality            
control of the sequencing reactions, ​alignment to a reference genome or (​de novo assembled)              
transcriptome is one of the critical steps in translating the raw data into something quantitative. 
 
 Figure 4: Illustration of spliced alignment of       
RNA-seq fragments to a genome (top) and direct        
alignment to a transcriptome (bottom). Reads are       
designated by thick solid lines, while dashed arcs        
represent the pairing relationship between     
paired-end reads. This illustration depicts     
alignment to a single 4 exon gene consisting of 3          
distinct transcripts. In the spliced alignment (top),       
the left read of the rightmost pair is a         
junction-spanning alignment to the red-green exon      
boundary. In the direct alignment to the       
transcriptome (bottom), one observes how the      
same alignment (e.g., the alignment to the blue        
exon) is repeated for each transcript. 
 
Because the sequenced fragments are derived from cDNA corresponding to fully (or partially)             
spliced transcripts, reads will often span the boundaries of splice junctions (SJs), resulting in              
so-called “junction-spanning” reads (Figure 4). This results in contiguous read sequences           
whose constituent sub-sequences may be separated by tens of thousands of nucleotides on the              
genome. This poses a considerable computational challenge, as the position of splice junctions             
in spanning reads needs to be accurately identified for a read to be properly aligned. There are                 
two main approaches for handling spliced reads, each having its own challenges and benefits: a               
spliced alignment against a reference ​genome or unspliced alignment against a reference            
transcriptome (a database of all isoforms). A main challenge in spliced alignment against a              
 
 reference genome is the proper alignment of reads that span a SJ, especially when these               
junctions are not annotated ​a priori​. Meanwhile, the main challenge in unspliced alignment to a               
transcriptome is the redundant sequence among related isoforms, which often leads to a high              
multi-mapping rate.  
Spliced alignment to a reference genome 
A popular solution for handling alignments of RNA-seq data is to use a splice-aware aligner.               
Early RNA-seq aligners, e.g., TopHat ​[52]​, make use of DNA-seq aligners, such as Bowtie ​[53]​,               
by first building a catalog of putative SJs to which the reads can be directly aligned. 
 
More recent splice-aware alignment tools ​[54–64] account for read splicing directly. They also             
can utilize the locations of known SJs and discover previously unannotated SJs. When a read               
partially aligns, the annotated SJ database is consulted to check if the alignment ends              
prematurely as the result of the read spanning a known splice site. In this case, compatible                
downstream splice sites can be considered as candidate loci to align the remaining portion of               
the read. Even if no annotated splice site exists at the point where the alignment ends, the tool                  
can interrogate the terminal nucleotides in the partial alignment to see if they are compatible               
with known canonical (or user provided) donor or acceptor sites, providing evidence that the              
partial alignment stops as the result of a splicing event. 
 
One of the primary difficulties in aligning reads across SJs is that only a small portion of the                  
read spans into one of the exons. Splice-aware aligners including STAR ​[55]​, HISAT(2) ​[56]​,              
Subread ​[57] and GMAP ​[58]​, attempt to deal with such cases by using evidence from reads                
that confidently align across SJs. In such strategies, new SJs are added to the index when they                 
display “high-confidence” evidence, i.e., when multiple reads with sufficient anchoring sequence           
span the SJ. Subsequently, the trusted SJs are used to help align reads that start or end near                  
the junction boundaries.  
Unspliced alignment to a reference transcriptome 
In organisms where transcriptomes are well-characterized, an alternative to splice-aware          
genome alignment is direct transcriptome alignment, which consists of aligning against a set of              
known transcripts. Since the transcript sequences are already spliced, reads should align            
contiguously and many of the computationally expensive steps and heuristics can be avoided.             
Moreover, when no reasonable quality reference genome is available for reference-based           
transcript assembly (e.g., when a transcriptome has been assembled ​de novo​), alignment            
directly to the assembled transcripts is the only available option. However, transcriptome            
alignment induces a high degree of multi-mapping and dealing with this becomes a primary              
computational challenge. For example, if a gene has 3 distinct isoforms, a constitutive exon of               
this gene will appear 3 times in the transcriptome reference (e.g., the blue exon in Fig 4).                 
Additionally, mapping only to annotated transcripts gives no capability to find novel splicing or              
expression patterns (e.g., novel exons) and it becomes difficult to assess retained introns or              
partial splicing; of course, it is possible to augment the transcriptome with unspliced variants.              
 
 The choice of genome versus transcriptome alignment is largely driven by the desired target              
application, and the constraints of downstream analyses. 
Gene- and transcript-level quantification from RNA-seq data  
One of the main uses of RNA-seq is to assess gene- and transcript-level abundances. Accurate               
abundance estimation is crucial to common downstream applications, including assessing all           
the notions of DE. Most commonly, abundances are estimated at the level of “genes”, but               
recently transcript-level abundances have also become more widely used, and there are            
inherent tradeoffs in choosing between the two levels of resolution. 
 
Gene-level quantification consists of assigning fragments (reads or read pairs) to “genes”,            
where gene is often taken to represent the amalgamation of all transcripts produced from a               
specific strand at a specific locus ​[65]​, which typically share some exons or parts of exons. The                 
total expression of a gene is the sum of expression of its isoforms. Any fragment arising from                 
any isoform of a gene is assigned to the underlying gene. There are typically two paths that can                  
be taken to obtain gene-level quantifications: direct fragment ​overlap counting of gene features,             
and transcript-level quantification followed by aggregation to the gene level. 
 
Direct fragment counting of gene features is done by first mapping RNA-seq reads to the               
genome with a splice-aware aligner, and then using a tool like featureCounts ​[66]​, HTSeq ​[67]​,               
or the built-in capability of STAR ​[55]​, to assess how many fragments overlap each gene; the                
same approach can be used to quantify other disjoint genomic features, such as             
non-overlapping exonic segments. Even in this basic pipeline, there are many variations of how              
certain conditions should be handled. For example, should a fragment reside completely within             
a feature to be counted? If a fragment maps to multiple features, should it be discarded,                
counted toward each feature, or somehow partially allocated? Of course, direct fragment            
counting approaches exhibit desirable features: they are conceptually simple and are typically            
quite fast. Conversely, they suffer from various disadvantages: they have no principled way of              
handling multi-mapping reads (e.g., arising from paralogous genes), and they are oblivious to             
potentially important compositional changes that are not reflected directly in gene-level read            
counts (e.g., isoform switching). Additionally, since such methods assess the frequency of reads             
overlapping a gene, they must grapple with the concept of gene definition. For example, should               
a gene be considered to be the union of exons of all transcripts of the gene, or the intersection?                   
Should intronic reads be included? Though the notion of the gene is a useful abstraction,               
transcripts are assayed in RNA-seq, and so present a conceptually cleaner target for             
quantification. 
 
 
  
Figure 5: Illustration of alignment of various reads to a gene with 3 isoforms (B - blue; G - green; R - red). In this                         
example, we wish to estimate the abundances of these isoforms, but the majority of reads have ambiguous origins                  
and need to be probabilistically assigned to the transcripts (relative probabilities for each read is shown by the                  
magnitude of the three colors). Some reads are consistent only with the B and G transcripts (colored blue and                   
green, respectively) and a small number of reads uniquely align to a single transcript (single color). In the                  
expectation-maximization (or related) algorithm, given the current abundance estimates, fragments are           
probabilistically assigned to transcripts, and then estimated abundances are updated by summarizing the             
(proportional) allocations over all fragments; transcript abundance estimates are determined after iterating the             
procedure until convergence. 
 
Transcript-level quantification consists of the assignment of fragments to specific transcripts,           
which is fundamentally more challenging but has a number of advantages: it admits a clear               
interpretation since transcripts are what the cell expresses; it allows for improved biological             
resolution and allows decoding of potentially important biological changes, such as isoform            
switching; it is the most appropriate level to model and correct for technical biases ​[68–71]​; it                
provides a proper model for handling reads that multi-map, as failing to do so can lead to                 
systematically poor quantification for genes in gene families ​[72]​; solving the transcript-level            
abundance estimation problem implies a principled solution to aggregating to gene-level           
estimates ​[73–75]​. Conversely, transcript-level quantification is not without disadvantages:         
alternative splicing implies that many fragments are ambiguous in their origin, and they must be               
assigned probabilistically, necessitating the adoption of a model, which may fail to adequately             
 
 capture reality; this read ambiguity translates to additional uncertainty in the estimated transcript             
abundances. 
Transcript quantification  
 
Methods for transcript quantification are based primarily on defining a generative model of             
RNA-seq reads, and then trying to perform inference on this model to obtain the relevant               
quantities (i.e., transcript abundances); see schematic in Figure 5. ​There has been a             
tremendous amount of research aimed at solving the problem of quantifying transcript-level            
abundance from high-throughput sequencing data and here we describe a few major highlights             
along the arc this research has taken. 
    
Initial probabilistic frameworks for transcript identification and abundance estimation using EST           
(expressed sequence tags) data were already being developed before the wave of            
Illumina-based sequencing ​[76]​, but Jiang et al. ​[77] were among the first to attempt              
isoform-level abundance estimation using RNA-seq data. They define counts over exons and            
exon junctions as arising according to a Poisson model, and view transcripts as vectors of               
inclusion and exclusion of these exons and junctions. By expressing the likelihood of the model               
parameters given the observed data, they pose a statistical model that admits efficient             
inference, for which they both obtain the point estimate by gradient ascent, and provide              
estimates of the posterior distributions of the parameters via importance sampling. This work             
represents one of the first proper statistical formulations of the problem. However, the approach              
does not account for fragments that map to multiple genes, and requires annotations of              
transcripts in terms of the gene-transcript relationship as well as the exon and junction read               
inclusion matrix. 
 
Li et al. ​[73,78] proposed one of the most widely-adopted generative models for transcript              
quantification, RSEM. They define a fragment-level model of RNA-seq experiments in terms of             
sampling molecules from an underlying population, proportional to the product of their            
abundance and length, and then generate fragments from the sampled molecules. Primary            
quantities of interest, including the nucleotide fractions (the fraction of all sequenced nucleotides             
deriving from each transcript) and the transcript fractions (the fraction of all transcripts in the               
initial population that consists of each transcript species), are estimated, and can be directly              
converted into popular abundance units, such as transcripts per million (TPM) or estimated             
counts. Notably, they propose computing the maximum likelihood (ML) estimates using an            
expectation-maximization (EM) algorithm (see Figure 5), and introduce a modified Gibbs           
sampling procedure to allow estimating credible intervals for the abundance estimates ​[73]​. The             
model is quite general: it works at the fragment level; it can account for numerous               
protocol-related aspects, including single-end and paired-end sequencing, directional vs.         
unstranded protocols, various coverage biases, etc. Further, the model relies only on knowing             
the transcript sequences and not the relationships to genes or annotations of exons and SJs.               
Thus, it can be easily applied to both well-characterized or newly-assembled transcriptomes.            
 
 One drawback of adopting a fragment-level model, however, is that each EM iteration scales in               
the total number of alignments, which is indeed large in most RNA-seq experiments. 
 
Instead of trying to model each fragment individually, MMSeq focuses on modeling sufficient             
statistics ​[79,80]​. Reads are categorized into equivalence classes, where two reads are            
equivalent if they align to the same set of transcripts. The approach works both within and                
across genes, and does not require the shared regions giving rise to the equivalence classes to                
correspond to any known annotation (e.g., exon or SJ). MMSeq uses an EM method that works                
directly over these equivalence classes, allowing efficient inference of transcript-level          
abundance in this model. In addition to this ML approach, they also introduce a Gibbs sampling                
procedure that allows estimating transcript abundances using summary statistics from samples           
of the estimated posterior, which also allows the assessment of uncertainty in the             
transcript-level abundance estimation and for assessing groups of transcripts with correlated           
posterior estimates. It is worth noting that the underlying likelihood function of the equivalence              
class-based model is not equivalent to that of the fragment-level model in RSEM, although              
subsequent work explored other factorizations of the full fragment-level likelihood that either            
preserved equality with the RSEM model while speeding up inference ​[81]​, or sacrificed equality              
in an attempt to balance efficiency and fidelity ​[82,83]​. eXpress demonstrated how            
fragment-level inference could be made much more efficient by modifying the inferential            
algorithm itself (i.e., online-EM), rather than the factorization of the underlying likelihood function             
[84]​ ​[85]​.  
 
Cufflinks is widely known both as a reference-guided transcript assembly algorithm and a             
quantification tool ​[86]​. Quantification is either restricted to a reference annotation, or allows             
new transcripts to be identified via alignments; transcript abundances are estimated via an EM              
algorithm to determine the ML estimates given the observed data. While we do not focus on                
assembly methods here, it is worth mentioning that, given the close relationship between             
transcript identification (assembly) and quantification, numerous approaches attempt to solve          
both problems together, either stagewise or jointly ​[82,87–94]​. 
 
A model similar to RSEM that jointly performs quantification and DE, together with fully              
Bayesian inference, was introduced in BitSeq ​[95]​. BitSeq focused on sampling from the             
posterior distributions of transcript abundances, given the fragment alignments, giving accurate           
estimates ​[96] and useful information about posterior uncertainty and posterior correlation,           
which is used in the DE step ​[95]​. To combat the heavy computational requirements, Hensman               
et al. introduced a variational Bayesian (VB) approximation ​[97] that can be efficiently optimized.              
A VB approach to the transcript abundance estimation problem was introduced in TIGAR ​[98]​,              
where the VB EM algorithm was shown to outperform the standard EM algorithm. However,              
Hensman et al. ​[97] introduced a novel optimization procedure called VBNG (Variational            
Bayesian Natural Gradient), which is a gradient ascent algorithm that takes into account the              
information geometry ​[99] of the underlying problem. They also suggest that EM-based methods             
tend to find solutions near the boundary of the parameter space, and their quantifications are               
less robust than either fully Bayesian or variational Bayesian estimates ​[97]​. 
 
  
Many of the mentioned approaches, among others, simplify the model or improve the efficiency              
of the inferential procedure, but they all rely on full alignments of each read, which can be a                  
computationally intensive and time consuming process. Recently, a number of new methods            
bypass the alignment step, and instead adopt ​lightweight models for quantification. Sailfish            
defines the transcript abundance likelihood in terms of the constituent ​k-mers ​of the underlying              
transcriptome and their abundance in the read data ​[100]​. Since the k-mers are completely              
known in advance, the relevant equivalence classes can be pre-computed, which reduces the             
inferential problem to one of simply counting k-mers and performing inference via an EM              
algorithm, e.g., the SQUAREM algorithm ​[101]​. This approach increases the speed of            
abundance estimation by over an order of magnitude compared to full alignment approaches.             
Building on the idea of k-mer-based abundance estimation, RNA-skim takes the approach of             
Sailfish even further, identifying sets of distinctive k-mers, known as “sigmers” ​[102]​. Transcripts             
are clustered into groups, and sigmers are identified as k-mers that are unique to (and indicative                
of) each cluster. Quantification is then performed by counting the sigmers in the read data,               
instead of all k-mers, and the EM algorithm is used to estimate transcript abundances from               
sigmer equivalence class counts. While very fast, these k-mer based approaches do not retain              
the coherence of the k-mers along a read, which can reduce specificity, and they cannot easily                
estimate certain aspects of the generative model, like the fragment length distribution.            
Addressing these shortcomings, kallisto relies on the use of pseudo-alignments to directly            
compute the sufficient statistics of the equivalence-class-based model of transcript abundance           
estimation ​[103]​. This approach uses k-mers to identify the transcripts with which fragments are              
compatible, but does not treat the k-mers independently. The pseudo-alignments can be            
computed in such a way that equivalence class counts are generated without the need to               
consider or compute individual fragment to transcript alignments, and this can often be achieved              
by querying only a small number of the k-mers present in a fragment, making the approach very                 
efficient and allowing accurate estimation in the equivalence-class based model using an EM             
algorithm. Salmon is another lightweight quantification approach that avoids full alignments,           
although they can still be used as input ​[104]​; it uses a two-phase algorithm for transcript                
abundance estimation: an online phase using a stochastic collapsed VB inference algorithm            
[105]​, where abundances and auxiliary parameters (e.g., GC bias parameters,          
sequence-specific bias parameters, fragment length distribution) are estimated; updates are          
then made using mini-batches of mappings. Salmon uses a lightweight mapping algorithm to             
compute the likely transcripts, positions and orientations of origin of each fragment, and adopts              
a ​fragment-level GC bias modeling approach ​[71]​, which reduces mis-identification of expressed            
isoforms when read coverage is not uniform along the transcripts due to GC-content. In the               
offline phase, a factorized likelihood function is optimized until parameter convergence. The            
granularity of the likelihood factorization used by Salmon can be adjusted ​[83] in a way that                
allows one to tradeoff between the fragment model of RSEM and the count-based model of               
MMSeq. In the offline phase, the factorized likelihood is optimized using a VB EM algorithm ​[98]                
or a traditional EM algorithm. Combining the ideas of efficiently determining fragment-transcript            
compatibility with the sigmer concept of RNA-skim, Fleximer uses a new matching algorithm that              
makes use of sets of sigmers to determine the likely loci of origin of reads, instead of treating                  
 
 each sigmer independently ​[106]​. A generalized suffix tree is used to organize the reference              
sequences and a “segment graph” that demonstrates how segments of sequence are shared             
among reference transcripts is used to select an informative and robust set of sigmers for               
quantification. Reads are mapped against the reference by matching them to sigmers using a              
pre-computed automaton. This process produces a set of transcript equivalence classes, along            
with a corresponding count for each, which is sometimes referred to as transcript compatibility              
counts (TCC); these are used in conjunction with an EM algorithm to estimate transcript              
abundances.  
 
Due to their vastly improved speed, ease of use, and reduced computational requirements,             
“alignment-free” approaches have become popular for assessing transcript and gene-level          
abundance using RNA-seq data. Recent benchmarks ​[107–110] suggest that, in addition to            
being fast, such methods are capable of producing accurate abundance estimates — at least to               
the extent that simulation-based studies, sometimes adopting the assumed generative models           
of the quantification approaches, can be relied upon to assess such accuracy. However, work              
still remains to be done with respect to fast, accurate, and robust transcript-level quantification.              
For example, it is likely the case that the underlying models can be further improved to account                 
for complexities in the fragmentation patterns of molecules prior to sequencing ​[111]​, to better              
balance robustness and sample-specific accuracy ​[112]​, or to address as-yet-uncharacterized          
biases. Also, most of these approaches (lightweight and otherwise) assume that the annotation             
of transcripts to be quantified is complete. The accuracy of quantification can suffer when this is                
not the case, though it is possible to computationally flag transcripts whose estimates are              
unreliable ​[113]​. 
Basics of differential expression 
Following alignment and quantification, assessing ​differential expression (DE) from the          
estimated feature abundances is often the next challenge. We will first present a general context               
and describe the statistical frameworks and overall workflow. The starting point is a count table               
with rows representing features (e.g., genes) and columns representing samples (i.e.,           
experimental units). The goal of DE is to formulate and test a statistical hypothesis for each                
feature. Depending on the experimental design, the context and the research question, more             
complex analyses are often required. As such, we elaborate on further variations of the overall               
workflow in the ‘Variants of differential expression’ section. 
 
The general workflow involves the following steps (see Figure 6): filtering and normalization             
(preprocessing), specification of the statistical model and estimation of model parameters,           
statistical inference on the relevant parameters and adjustment for multiple testing. We            
introduce this general workflow from the perspective of classical models for count regression.             
Then, we discuss various notable deviations, including alternative estimation and inference           
frameworks and additional strategies to ensure robustness. 
 
 
 It is worth first considering the magnitude of the inferential problem. Typically, only a limited               
number of replicates are available (e.g., 3-5 replicates per condition). One can ponder on the               
achievable statistical power from such small sample sizes, even for a single feature, with the               
real interest lying in thousands of features simultaneously. This parallel inference challenge is             
common to various genome-scale experiments and the statistical community has contributed           
strategies to at least improve the overall performance; from this, a few themes have emerged.               
For example, in estimating parameters for a given feature, it is often beneficial to consider the                
information coming from the other features in the dataset ​[114]​. In general, genomics data is               
ripe for the use of empirical Bayes methods to moderate estimates, where priors for a feature                
are derived from a suitable set of other features measured in the dataset. In addition, it has                 
become clear that moderating ​variance parameters is critical and indeed much of the success of               
earlier parallel inference frameworks (e.g., for microarrays) can be attributed to variance            
moderation, whether this occurs in an ​ad hoc strategy ​[115] or in hierarchical models ​[116]​.               
Other “tricks”, such as regularization of regression parameters or considerations for robustness,            
provide additional performance benefits. Taken together, the challenges associated with vast           
parallel inference can be greatly eased by adopting one or more of these strategies. 
 
 
Figure 6: Schematic overview of a DE       
analysis for RNA-seq data. The red      
boxes correspond to pipelines for     
count-based models (e.g.,   
edgeR,DESeq2), while the blue boxes     
correspond to a linear model based      
pipeline (e.g., limma-voom). 
Preprocessing: filtering and normalization 
The vast number of features in a typical RNA-seq experiment leads to a large multiple testing                
burden. However, many features are largely uninformative, e.g., features with low expression            
provide little evidence for DE. Therefore, filtering strategies are employed that predominantly            
remove uninformative features and reduce the multiple testing burden. Bourgon et al. ​[117]             
showed that filtering is valid if it is independent of the DE test statistic; thus, filtering on residual                  
variance is invalid, while filtering on expression strength, as is commonly done, is valid.  
 
  
The observed counts of the features cannot be directly compared across samples, since there              
are differences in sequencing depth across libraries. Several methods have been developed to             
“normalize” counts to facilitate across-sample comparisons, although in most count-based          
models, the counts themselves are not modified and instead scaling factors accompany the             
analysis. Initial attempts focused on a simple correction for sequencing depth, using the total              
sum of counts for each sample (i.e., the library size) as a scaling factor ​[3,118]​. However,                
variation in library preparation or RNA composition between samples also contribute to            
between-sample variability, and should be accounted for ​[119]​. In addition, a few highly             
expressed genes can largely drive the sampling of fragments, thus leading to inaccurate scaling              
of the counts. A popular approach is to calculate a size factor ​[119,120]​for each sample. This                
can be considered to be a robust global fold change between the current sample and a                
(pseudo-)reference sample derived from all samples. DESeq’s median-of-ratio and edgeR’s          
trimmed mean of M-values (TMM, where M-values denote empirical fold changes between two             
samples) method are the most popular scaling approaches ​[121]​. Both procedures assume that             
the majority of genes are indeed not DE, and adopt robust summarization methods to calculate               
the size factors (effective library sizes) in order to reduce the impact of DE genes (TMM: a                 
trimmed weighted mean; DESeq: median of the log-expression ratios). More advanced           
normalization methods have since emerged, to address other technical artifacts such as GC             
content and transcript length effects, and to accommodate within- and between-lane           
normalisation, e.g., CQN: ​[122]​; EDASEQ: ​[123]​. Moreover, methods based on external spike-in            
features have been introduced to address normalization for applications where many features            
are DE or where the basic assumptions of conventional normalization methods are violated             
[124–126]​. Recently, a normalization technique has been proposed for RNA-seq data with large             
differences between conditions that assumes similar distributions in biological replicates, while           
accommodating for differences between conditions ​[127]​.  
 
The normalization size factors are built into the DE analysis workflow as ​offsets in the statistical                
models (see below). Notably, size factors are treated as fixed and known, while they are               
actually random variables that have been estimated from the data ​[128]​, and it is unclear how                
ignoring their associated uncertainty affects the downstream DE analysis. 
 
 
 
  
Figure 7: (A) A mean-dispersion plot of the RNA-seq experiment from ​[129]​, as processed in ​[130]​. The dispersion                  
smoothly decreases for genes with higher expression and eventually reaches an asymptote, which can be               
considered as the biological variability that is present in the dataset. (B) MA-plot of the same RNA-seq experiment.                  
The y-axis shows the log-fold-change (M) and the x-axis shows the mean of normalized counts (A). The variability                  
on the fold changes is higher for lowly expressed genes, which is intrinsic to count data. Red points denote DE                    
detection according to an FDR threshold of 0.05. 
 
Modeling and Estimation 
Because of the typically small sample size, DE tools mainly implement parametric methods             
[120,131–134]​. Initially, count data were log-transformed and linear models were used for DE             
analysis ​[4]​. However, log-transformed counts suffer from ​heteroscedasticity (a systematic          
mean-variance trend) intrinsic to count data, rendering analysis with the standard linear model,             
which assumes homoscedasticity, suboptimal. In addition, fitting continuous models to          
(transformed) count data introduces a further approximation. Therefore discrete count          
distributions gained more traction in the initial frameworks.  
 
Gene expression variability across technical replicates (i.e., resequencing the same sample),           
so-called ​shot noise​, has been shown to approximately follow a Poisson distribution ​[118]​, for              
which the variance is equal to the mean. Biological replication introduces additional            
between-sample variability and analysis frameworks therefore resorted to one of the natural            
extensions, the gamma-Poisson or negative binomial (NB) distribution, which has an additional            
dispersion ​parameter and a quadratic mean-variance relationship: 
Y  B(μ ,  φ )f i ~ N f i  f   
ar(Y ) μ μ ,V f i =  f i + φf 2f i
 
 
 
 
 where denotes the read count of feature ​f in sample ​i​, is the dispersion for feature ​f and Y f i           φf         
represents the average expression, which is driven by the true (relative) mRNAθμf i = si f i             
concentration in the sample, , multiplied by a normalization scaling factor, ; there also    θf i        si    
exists a characteristic dispersion-mean trend in RNA-seq datasets (Figure 7A). Initial           
implementations focused on two-group comparisons ​[120,135] and were later extended to the            
generalized linear model (GLM) framework, an extension of classical linear models to            
non-Gaussian responses ​[136]​. GLMs allow for the inclusion of multiple treatments or            
covariates, thus broadening the applicability. The NB GLM model can be formulated as: 
Y  B(μ ,  φ )f i ~ N f i  f   
og(μ ) l f i = ηf i  
log(s )ηf i = X βi f   +  i   
where is the linear predictor, denotes the design matrix, represents the regression ηf i     X i      βf      
parameters and are scaling (normalization) offsets. Regardless of the model, the  log (s )i           
parameters or, equivalently, (a linear contrast of) , would represent the parameter(s) of θf i       βf        
interest for inference. 
 
Reliable estimation of the dispersion parameter is non-trivial due to limited sample sizes.      φf         
Traditional ML estimators for the dispersion are negatively biased ​[137]​, since they do not              
account for the fact that the mean is also estimated from the data. Early implementations               
estimated a single common dispersion parameter for all features ​[137]​, with the rationale to              
obtain a stable estimate by borrowing strength over all genes. However, the common dispersion              
assumption is unrealistic and relaxed estimation schemes were proposed, such as moderation            
toward a common dispersion ​[135]​, or estimation in strata of similar expression strength ​[120]​.              
For example, DESeq adopts a method of moments (MM) estimator and assumes the dispersion              
to be a smooth function of the mean. In order to avoid too liberal inference, the dispersion is                  
then set as the ​maximum between the smooth fit and the gene-wise MM estimate; however,               
while robust to outliers, this method tends to overestimate the variance and is therefore              
conservative ​[138,139]​. Later approaches resorted to an approximate conditional inference          
scheme, the Cox-Reid adjusted profile likelihood (APL) ​[140]​, to correct for the bias in the ML                
estimator ​[136]​. Again, stable estimation is provided by leveraging information across genes            
(Figure 8). In particular, edgeR uses a maximized weighted APL to tradeoff between             
gene-specific and shared dispersion estimators upon estimating the dispersion-mean trend          
across all genes (similar to DESeq). The weighted likelihood:  
PL (φ )  G APL (φ )A f f  +  0 sf f   
consists of the APL for a specific feature ​f (first component), and a shared likelihood (second                
component), which can be interpreted as a prior from a Bayesian perspective, thus representing              
an approximate empirical Bayes solution ​[135]​. The weight given to the prior likelihood ( ) can             G0   
also be estimated from the data ​[141]​. Analogously, Dispersion Shrinkage for Sequencing            
(DSS) and DESeq2 model the log( ) as a Gaussian random variable, and Bayes formula is     φf           
applied to generate a posterior mode for each gene ​[131,142]​. Hyperparameters for the             
 
 (Gaussian) prior are inferred from the data, using either the MM or Cox-Reid estimator across all                
genes.  
 
 
Figure 8: Empirical Bayes. In an RNA-seq       
experiment, the observed differences in gene      
expression across groups of samples with      
respect to within-group variance is assessed.      
The unobserved population distribution for     
the true within-group variance of each gene is        
depicted with a purple curve. Variances are       
estimated from limited sample size     
experiments, and so there is sampling      
variance in our estimate of the variance       
(orange curves). A ML estimate or a       
bias-corrected estimator for expression    
variance can be used (black arrow).      
Thousands of genes are typically observed      
and estimates are made for each, providing       
an empirical distribution of ML estimates      
across all genes (red curve). This empirical       
distribution of ML estimates can be used to        
determine a prior distribution for empirical      
Bayes analysis; the posterior distribution for      
the variance of each gene is calculated using        
Bayes formula. The maximum a posteriori      
(MAP), or posterior mode, represents a      
"shrunken estimate" (blue arrow), where the      
amount of shrinkage is determined by the       
shape of the likelihood and the width of the         
prior distribution. 
 
Once dispersion estimates are available, the parameters of the mean model, , can be           βf     
estimated using standard algorithms for GLMs. 
Statistical inference 
After fitting a GLM to each feature, the statistical inference involves testing the null hypothesis               
H​0 that there is no DE between conditions, e.g., that the log-fold-change is zero (​LFC ​= 0​)​,                 
against the alternative ​H​1 ​that the LFC differs from zero (​LFC ​≠ 0​). In the GLM framework, the                  
null hypothesis can be represented either as a single regression parameter or a linear              
combination of parameters (contrasts), which is defined by a vector or matrix L so that ​H​0​:                
LFC=L =0​. Indeed, a regression parameter in a NB-GLM with canonical link function can beβf               
interpreted as a log-fold-change between groups and thus provides a measure of effect size. 
There are multiple hypothesis tests available for GLMs with known (asymptotic) distribution            
under the null. Likelihood ratio tests (LRTs) compare the likelihood of a full model, upon               
estimating all parameters without constraints, with the likelihood of a reduced model, where one              
or some of the parameters are constrained according to ​H​0​. LRT statistics are asymptotically              
chi-squared distributed under ​H​0 and this type of test is implemented in both edgeR and               
DESeq2. By default, however, DESeq2 adopts a Wald test. Wald tests are attractive from a               
computational point of view, since they only require fitting the full model and calculating the               
 
 variance-covariance matrix of the regression coefficients. The Wald test statistic for a single             
model parameter or a single contrast W = /se(LFC) asymptotically follows a standard             
normal distribution under ​H​0​, where se(.) indicates the standard error and is the ML               
estimate of LFC. From ML theory, it is known that LRTs have better properties (e.g., invariance                
to transformation) than Wald tests in GLMs ​[143]​; however, RNA-seq tools moderate dispersion             
estimates and do not re-estimate them under ​H​0​, so it is unclear whether these benefits carry                
over to RNA-seq data analysis in practice. 
Multiple testing 
The p-values obtained from the statistical inference must be corrected for multiple testing to              
avoid excess false positives. While it is possible to control the probability of returning at least                
one false positive in the list of detections by adopting family wise error rate (FWER) corrections,                
this stringent form of correction is overly conservative. Indeed, when screening many thousands             
of features, one is typically willing to tolerate a certain proportion of false positives in order to                 
obtain a larger number of true positives. The false discovery rate (FDR), which gained              
significant popularity, controls the expected fraction of false positives in the detected set of              
features, i.e., FDR = E[V/max(R,1)], where V is the number of false positive rejections and R the                 
total number of detections. The FDR was introduced in the seminal paper of Benjamini &               
Hochberg ​[144] and has become common practice in high-dimensional data analyses because            
of its simplicity and solid theoretical justification. Indeed, it can be shown that the FDR is                
justified under a range of dependency structures between the genes ​[145] and can be              
approached from both frequentist and Bayesian perspectives. 
Variations to the general workflow 
There is a large and growing number of alternatives to the basic framework mentioned above:               
different inference based on the same models, alternative models, more robust approaches,            
different testing regimes, variations on multiple testing corrections and so on. In this section, we               
summarize some of the many developments. 
 
Alternative models (inference frameworks)​. NB count models, which underpin many DE tools,            
assume a quadratic mean-variance relationship. Inference, however, may benefit from a more            
flexible variance structure and, for this, other models have been proposed. One strategy uses              
quasi-likelihood (QL), which requires that mean and variance are specified to be able to make               
inference on the mean model parameters ​[146]​. The QL method adopts the same mean model               
structure as the NB, but introduces an additional overdispersion parameter, such that ​var(Y​fi​) =              
𝜓​f ( ); 𝜓​f is estimated using a moderated MM estimator. QL naturally allows  μμf i + φf 2f i
 
 
            
(asymptotic) hypothesis tests based on t- and F-statistics, thus accommodating the uncertainty            
in the estimation of the additional QL dispersion parameter. Another variation is the use of a                
more flexible distribution, such as the negative binomial power distribution, which adds an             
additional parameter ​[147] to the NB. Within the NB framework itself, Bayesian methods have              
also been developed. A fully Bayesian approach has the benefit that various aspects of the               
 
 posterior can be reported (e.g., credible intervals) and the degree of parameter shrinkage             
naturally depends on the amount of information available for that gene (a trade-off between              
expression magnitude, dispersion and residual degrees of freedom). One of the early methods             
was ShrinkBayes, a fully Bayesian approach that included multiple mixture priors (e.g.,            
Gaussian) ​[148,149] and where fitting was accomplished using Integrated nested Laplace           
approximations (INLA) ​[150]​, which avoids the Markov Chain Monte Carlo sampling. Another            
alternative is to remain within computationally and inferentially efficient Gaussian linear models,            
after suitably transforming the (normalized) count data. For example, limma-voom models           
log-transformed normalized counts using a linear model while adjusting for heteroskedasticity           
via weighted regression, where the observation weights are computed from the observed            
variance-mean relationship ​[151]​. In this case, moderated t- and F-statistics are used for             
inference. Finally, non-parametric methods have been developed, which are more robust to            
outliers and do not require distributional assumptions. For example, SAMSeq ​[152]​, adopts the             
Wilcoxon test to assess DE between groups, and uses resampling procedures to adjust for              
differences in sequencing depth. 
 
Robust LFC estimation​. The standard NB workflow typically makes use of APL NB likelihood for               
parameter estimation, combined with empirical Bayes procedures to borrow strength across           
features when estimating the dispersion parameter. There are two related challenges: i) ratios of              
smaller counts result in more variable LFCs (Figure 7B); ii) estimation of LFC can be sensitive to                 
outliers. This makes a ranking of genes according to LFC difficult, since lowly expressed or               
outlier-affected genes are likely to dominate the top list. In order to derive more robust LFC                
estimates, several approaches have been adopted. First, the use of “prior counts” in the              
numerator and denominator of the LFC; effective shrinkage is accomplished by augmenting            
each count with a carefully chosen value, although the optimal value may vary across datasets.               
Second, edgeR-robust ​[139]​, for instance, adopts an M-estimation approach by iteratively           
downweighting outlying observations within the GLM fitting procedure, dampening the effect of            
outliers on both mean and variance estimates. Alternatively, outliers can be identified and             
removed and/or imputed by taking advantage of the remaining data for a feature ​[131]​. Lastly,               
priors can be imposed on the LFC parameters. For example, DESeq2 includes a zero-centered              
Gaussian prior in the NB GLM and provides the posterior mode of LFC as output ​[131]​. The                 
width of the prior is set conservatively, using a weighted upper quantile of the observed               
log-fold-changes. New alternative shrinkage estimators in DESeq2 incorporate priors with          
heavier tails that introduce less bias, using either a mixture of Normals ​[153] or a Cauchy                
distribution ​[154]​. 
 
Accounting for unobserved effects​. As mentioned, (G)LMs can adjust for known confounders.            
However, genomic data can also be affected by unknown, hence unobserved, confounders.            
This problem is widespread in publicly available data, which typically do not contain sufficient              
metadata on potential batch effects caused by lab, protocol, date, etc. Batch correction methods              
can leverage the parallel structure of high throughput transcriptomic data to identify unknown             
and unobserved systematic effects. SVA ​[155,156] and RUV ​[125]​, for instance, estimate            
surrogate variables through singular value decomposition on control features or on a matrix of              
 
 model residuals so as to avoid that the phenotypic effect of interest is captured by the                
surrogates. RUV also has the option to exploit information in replicate samples. The estimated              
surrogate variables can subsequently be included as predictors in the statistical model to adjust              
for the batch effects. 
 
Statistical inference by testing against a threshold​. The standard approach for detecting DE in              
RNA-seq involves a simple null hypothesis: ​H​0​: LFC=0​. However, statistical significance does            
not guarantee that the fold changes are large enough to be biologically relevant. Analysts often               
produce candidate gene lists by applying a threshold on the magnitude of the LFC, but the                
statistical properties of this approach are unclear. The FDR is a ​set property and has no                
interpretation when the set, post-FDR calculation, is altered ​[157]​. To address these practical             
and theoretical concerns, several tools have adopted tests relative to a LFC threshold, a              
procedure initially proposed for microarray data ​[158]​. This results in a composite null             
hypothesis, such as ​H​0​: |LFC|<a​. Implementations differ; for example, DESeq2 replaces the            
composite null with a simple null hypothesis at the boundary of the parameter space ​[131]​;               
edgeR uses a modified likelihood ratio test or a quasi-likelihood F-test against a threshold ​[159]​. 
 
Small-sample inference​. The null distributions for Wald or LRT statistics for count models are              
only valid asymptotically and the number of replicates is often too low for these approximations               
to be fully effective, which may lead to inflated FDR. Initial implementations provided exact tests               
[137]​, but these can only be applied in simple designs. Another strategy is “small sample               
asymptotics”, essentially making use of higher-order approximations that are still compatible           
with the GLM framework ​[160]​. 
  
Multiple testing​. While the FDR achieves a more reasonable sensitivity-specificity tradeoff than            
family wise error rate correction approaches, other developments beyond simple filtering aim to             
further reduce the multiple testing burden. Storey's q-value, for instance, estimates the            
proportion of true null hypotheses from the data to increase power ​[161]​, while others adopt a                
data-driven ​weighting of the p-values in the FDR correction ​[162]​. Although the FDR is deeply               
rooted in statistical theory, it is not guaranteed that methods will control error rates at the                
nominal level in real applications. NB methods, for instance, rely on the asymptotic theory,              
which might not hold for applications with low sample sizes. A study has suggested that               
co-regulation of genes induces intergene correlations, which can alter the null distribution of the              
statistical test ​[163]​; local FDR approaches were introduced that empirically estimate the null             
distribution ​[164]​. Other developments address issues in testing many hypotheses for every            
gene (e.g., multifactorial designs). The conventional approach is to control the FDR on each              
hypothesis, but this does not allow for straightforward prioritisation, since genes typically have a              
different ranking for each hypothesis. Stage-wise testing procedures can be interpreted as a             
generalisation of analysis of variance with post-hoc tests towards a high throughput context             
[165,166]​, thus allowing a natural ordering of the genes according to an “omnibus” (all effects of                
interest) test, while providing FDR control at the gene level. 
 
 Variants of differential expression 
The previous section introduced count-based DE in general terms: each row of a count matrix is                
submitted to a statistical model (often by first estimating moderated variance parameters over             
the whole dataset) and hypothesis tests of interest are conducted, with an adjustment for              
multiple testing. In this section, we unravel a set of additional approaches to interrogate              
RNA-seq data in terms of DE. 
 
Although it may be obvious that DE is of interest, this can manifest or be defined in multiple                  
ways (see Schematic Figure 9). It is important to remember that while one may want to cast                 
inferences to the gene level, measurements are made at the fragment level. We use the term                
differential gene expression (DGE) to refer to hypothesis testing related to the ​total outcome of               
an annotated gene, either by comparing accumulated transcript-per-million (TPM) estimates or           
by comparing raw counts while including an adjustment for average transcript length via offsets              
[74]​. If the expression of transcripts is the feature of interest (independent of other transcripts),               
differential transcript expression (DTE) analyses can be conducted. Alternatively, one could be            
interested in whether ​at least one transcript from a gene is DE. This requires statistical testing at                 
the transcript level and then ​aggregation to the gene level. Yet another strategy is to consider                
whether the relative abundance (i.e., proportions) of transcripts for a specific genomic locus             
changes between conditions, which is commonly referred to as differential transcript usage            
(DTU) or, more generally, differential splicing (DS). A surrogate for DTU, differential exon usage              
(DEU), is conducted on exon-level quantifications; in this case, the goal is to identify exons that                
deviate from proportional expression to separate differential usage from DE. Yet another            
alternative is to quantify and test differences at the ​event level​, where reads supporting (or not                
supporting) an event (e.g., inclusion of a cassette exon) are summarized and compared ​[167]​. 
 
There is certainly a question of which analysis path to choose. Conceptually, pure DTE points to                
all kinds of DE and while casting a wide net of potentially interesting genes might seem                
appealing, there are some considerations to be made. For example, if a given transcript is DE,                
often the question becomes: what happens to the expression of the other transcripts for this               
gene? Are all transcripts changing in the same direction? If so, it may be better in terms of                  
sensitivity to detect an aggregated output (i.e., DGE). Or, transcript-level expression can be             
represented as a gene-wise multivariate outcome and isoform switches considered collectively,           
i.e., by assessing DTU, which is not affected, in either direction, by DGE. DTU implies DTE                
while the opposite is not necessary true. Generally speaking, we favor the strategy of two clear                
but orthogonal analyses (DGE and DTU), over a catch-all DTE analysis ​[74]​, but this will               
ultimately be application dependent and scientists should clearly define their question of interest             
in advance. 
 
 Differential transcript expression  
Modeling transcript-level count data for DE presents some additional challenges due to            
increased variability and resolution compared to gene-level analyses. For example,          
transcript-level abundance estimates are considerably more variable than gene-level counts due           
to ambiguous assignment of fragments to isoforms ​[74]​. Thus, transcript quantifications inferred            
by popular tools such as RSEM, Salmon or kallisto, carry a higher degree of uncertainty, which                
should be accounted for in the downstream DE analysis. 
 
 Figure 9: Schematic illustration of some examples of DGE,         
DTE and DTU for a gene with three isoforms (Isoform 1, 2            
and 3) in a two group comparison (A vs B). Bars marked            
with an asterisk indicate DTE in group B relative to group A. 
 
Transcript quantifications still have many of the properties of count data (e.g., mean-variance             
relationships) and thus could be used as inputs to the frameworks mentioned above. However,              
quantifications are estimates that may obscure inference when plugging them into count-based            
RNA-seq tools. Cufflinks was one of the first methods to use estimated abundances and their               
corresponding standard errors to perform DTE (and also DGE) analyses; ​the method quantifies             
transcript abundances via a likelihood model and EM algorithm and tests of DE are performed               
by applying the delta method on the abundance parameters ​[75,86]​. Bayesian approaches for             
identifying DTE based on estimated counts, e.g., ranking via Bayes factors, include EBSeq             
[134]​, which uses an empirical Bayesian hierarchical model, and MMSeq ​[79,168]​, which fits a              
linear mixed model to data via Markov Chain Monte Carlo techniques. Similarly, BitSeq (and              
later cjBitSeq) introduced a generative model that couples both quantification and DE using fully              
Bayesian inference ​[95,169]​. Most recently, with the advent of ultrafast transcript quantification            
algorithms, sleuth uses bootstrap samples of each sample of reads to determine the so-called              
 
 “inferential variance” and integrates this into the DE calculation through a variance components             
model on the log-transformed scale ​[170]​. 
Differential transcript usage (differential splicing) 
One of the first statistical models for DTU, cuffdiff, calculates the square root of the Jensen-                
Shannon divergence on estimated ​transcript ​proportions​, and uses the delta method to estimate             
the variance of this metric under the null hypothesis of no change in proportions ​[86]​. Another                
conceptually distinct approach formulates a Poisson mixed-effects model on exon- and           
junction-level quantifications and searches for exon-condition interactions that represent         
differential usage ​[171]​. Such ​departure-from-parallelism ​modeling was introduced in earlier          
analyses of probe-level microarray data for DTU ​[172]​; on RNA-seq data, this approach was              
further formalized with DEXSeq ​[173]​, where a NB model on exon-level counts is formulated.              
Exon by exon, DEXSeq tests whether an improvement in fit is achieved by adding a single                
exon-condition interaction, which represents the differential usage of that exon across           
conditions. A comparison study showed that DEXSeq has a good performance in            
well-annotated transcriptomes and that filtering of lowly expressed transcripts improves error           
control ​[174]​; in addition, DEXSeq also works well with transcript quantifications as input ​[175]​. 
 
In a similar vein, DRIMSeq ​[176] and LeafCutter ​[177] employ the Dirichlet-Multinomial (DM)             
distribution to perform the same inference task, but treat the output of a gene’s expression as a                 
multivariate response; Bayesian inference for the DM model has also been considered in             
BayesDRIMSeq ​[178]​. Several tools neglect the uncertainty in estimated transcript-level counts           
and this is perhaps the reason for inflated FDRs ​[175]​. To address this, RATs uses               
bootstrapped (transcript-level) quantifications to infer DTU via a G-test of independence, based            
on the multinomial distribution, on the two groups’ isoform counts ​[179]​. Bayesian methods,             
such as cjBitSeq ​[169]​, instead of considering estimated counts and their uncertainties, focus on              
the group of transcripts that each read is compatible with (i.e., equivalence classes). In this way,                
quantification is not required because the DS tools treat the transcript allocation of reads as an                
unknown latent variable. 
Event-level analyses based on percent-spliced-in 
Some methods perform differential analyses based on percent-spliced-in (PSI) values. PSIs can            
be computed either for specific events (retained intron, cassette exon, etc.) or at the transcript               
level, and indicate the fraction of RNA-seq reads supporting the event, obtained as the ratio               
between the number of reads including the event and the total number of reads including and                
excluding the event. The difference of the PSIs between conditions is then used to assess DS,                
performed separately for each event (or transcript). Some of the main DS tools based on PSIs                
include: ​rMATS ​[180]​, which uses a LRT, and ​SUPPA2 ​[181]​, whose test is based on comparing                
the observed difference in PSIs across conditions to the empirical cumulative density function of              
the within-replicates differences of PSIs of splice junctions from similarly expressed transcripts. 
 
 
 Event-level analysis, similar to DEXSeq’s exon-level approach, separately focuses on each           
splicing event and results could be aggregated to the gene level by considering the most               
significant event- or transcript-level test, appropriately adjusted for multiple testing          
[173,181,182]​. 
Multi stage testing 
As mentioned, DS analyses can be approached at the gene-, transcript- or event-specific level.              
While gene-level tests often have higher sensitivity, testing each individual transcript provides            
increased resolution. However, neither gene- nor transcript-level tests guarantee FDR control           
on the full set. Stage-wise testing procedures ​[165,166]​, instead, first screen for significant             
genes, and only consider significant transcripts from those genes. This procedure gives            
gene-level FDR control and allows researchers to leverage the power from gene-level tests             
while allowing them to interpret results at the transcript level ​[175]​. The same procedure can be                
applied replacing transcript-level tests with exon- or event-specific tests. 
Single Cell Transcriptome Sequencing 
One of the emerging data types in transcriptomics is single cell RNA-seq (scRNA-seq), whereby              
the expressed content of individual cells is prepared and sequenced. In this case, experimental              
design is again of critical importance to avoid confounding ​[183]​. Experimentally, capture and             
reverse transcription efficiency become important, given that the number of mRNA transcripts            
per mammalian cell is estimated to vary between 50k and 300k ​[184]​.  
 
Two main experimental approaches are used: plate-based, where cells are sorted into individual             
wells for lysis and library preparation; or, droplet-based, where each cell is absorbed (together              
with reagents) and processed within an oil droplet ​[185]​. Several variations of these protocols              
are now available, increasing the number of cells assayed, but ultimately only a small fraction of                
the expressed RNAs (cDNAs), often the most highly expressed transcripts, are captured. The             
features that distinguish scRNA-seq from bulk RNA-seq data include: i) generally low depth of              
sampling for each cell (due to cost, but also due to lower diversity of cDNA fragments); ii)                 
so-called “dropout” where a cell expresses a transcript but it is unobserved; and, iii) higher               
levels of biological (since no averaging) and technical (e.g., more amplification) variation. 
 
Nonetheless, researchers are able to distinguish cell “identities”, where identity represents the            
combined effects of cell “type” (permanent feature) and cell “state” (transient feature) ​[186]​. The              
Human Cell Atlas, amongst other projects, opens the door for exploring spatial context ​[187]​,              
developmental patterns ​[188]​, immune responses ​[189]​, response to therapy ​[190]​, and an            
increasing range of basic science and clinical investigations ​[191–193]​.  
 
Although many computational aspects of scRNA-seq data are beyond the scope of this review              
(e.g., dimensionality reduction techniques, ordering cells into lineages), one connected          
application area that has already received considerable attention is DE analysis. In the simplest              
 
 setting, cells are first partitioned into different classes (e.g., assumed to correspond to different              
cell types) via clustering, with the subsequent aim of finding markers for each cluster, e.g., to                
annotate cell types. To perform this task, a statistical model uses ​cells as experimental units, as                
opposed to samples in bulk analyses; thus it is worth considering the population to which the                
conclusions extrapolate to. 
 
To date, several methods have been developed to decipher DE between cell types, many of               
which have been comparatively assessed in recent benchmarks ​[194,195]​. Many of these            
single-cell-specific methods are extensions or variations of existing bulk approaches. For           
example, SCDE formulated the RPM (read-per-million) data for a given gene across cells as a               
mixture of Poisson and negative binomial components; using a Bayesian approach, probabilities            
of observing a given fold change are converted into empirical p-values ​[196]​. MAST uses a               
hurdle model on log(TPM+1) data, where a logistic regression is used to model whether a gene                
is expressed or not and conditional on expression, a Gaussian linear model is used. Inferences               
for the two sets of regression parameters are done in a Bayesian framework that also provides                
regularization ​[197]​. Again, extending existing approaches, Van den Berge ​et al​. ​[198] proposed             
a zero-inflated NB (ZINB) model; model fitting is done within the ZINB-WaVE framework ​[199]​,              
estimating cell- and gene-specific posterior probabilities for counts to belong to the NB count              
component of the ZINB mixture model. These probabilities are used as observation weights in              
the downstream estimation of regression parameters in the classical NB framework. 
  
Nonetheless, many DE methods focus on assessing changes in the mean parameters. But             
since cell subsets are being compared, we may not expect to have simple shifts in the mean.                 
Instead, it may be informative to detect and understand changes in expression ​variability across              
conditions ​[200]​. Alternatively, full distributions (instead of means or variances) can be            
compared, as was proposed in a Bayesian framework in scDD ​[201]​, highlighting not only DE               
but also differential proportions (change in the relative usage of low and high expression),              
differential modality (change in the number and place of the mode of expression) or some               
combination thereof. 
 
In many applications of single-cell DE analysis, the “sample sizes” (numbers of cells) are              
generally larger than those commonly used within the optimized frameworks built for bulk             
RNA-seq data, and thus it seems that the distributional assumptions play less of a role for                
effective inference. Indeed, a recent comparison highlighted decent performance of t-tests and            
Wilcoxon rank-sum non-parametric tests in comparing single cell subsets ​[194]​. 
 
Beyond comparing cell types, which may or may not involve multiple experimental units (e.g.,              
patients), it will be of increasing interest to compare expression levels of genes ​across biological               
replicates and conditions. For example, it may be of interest to understand cell-type-specific             
immune responses following a stimulus. A recent study compared multiple patients across            
stimulated and unstimulated conditions by first computationally separating immune cell types           
[189]​; to do this, cells from a given cell type were ​aggregated into a “pseudo-bulk” RNA-seq                
dataset and DE was performed using standard tools. 
 
 Long Read Transcriptome Sequencing 
The short read length of Illumina-based RNA-seq complicates unambiguous placement of reads            
to the genome, especially in repeat regions ​[202]​, and adds difficulties to the assembly,              
identification and quantification of expressed isoforms ​[203–205]​. In contrast, so-called          
third-generation​, or long-read, sequencing technologies, led by Pacific Biosciences (PacBio)          
[206] and Oxford Nanopore Technologies (ONT), are able to generate reads that are much              
longer. By sequencing single molecules, they can also avoid the need for PCR amplification,              
hence reducing coverage biases ​[207,208]​. Currently, long-read technologies incur a higher           
average cost and a higher error rate than short read sequencing ​[203,209]​. However, this is a                
rapidly developing field and improvements in error rates and throughput are to be expected.  
 
The strategies employed by PacBio and ONT to generate long sequencing reads of single              
molecules differ in many ways. PacBio, with its RSII and Sequel instruments, uses SMRT              
(single molecule real time) sequencing ​[210]​, where the reactions take place inside so-called             
zero-mode waveguides (ZMWs) ​[211]​. At the bottom of each ZMW, there is a single DNA               
polymerase molecule. As the polymerase processes a DNA fragment, the incorporation of each             
nucleotide leads to a fluorescent signal, which is detected by the ZMW and converted to a base                 
call. A specific characteristic of the PacBio library preparation system is the creation of              
SMRTbell templates ​[212]​, which are obtained by ligating SMRTbell hairpin adapters. The result             
is a circular construct, where the two strands of the template are separated by adapters with                
known sequences. As the construct is processed by the polymerase in the ZMW, the original               
template can be passed multiple times. Since the sequencing errors are largely random ​[213]​,              
the base-level error rate can be considerably reduced by forming a consensus over these              
passes.  
 
ONT, in contrast, uses a different sequencing strategy, based on protein nanopores placed in a               
polymer membrane ​[214] for its MinION and PromethION sequencers. A current is passed             
through the nanopores, and as the template molecule is passed through the pore by a motor                
protein, each combination of bases induces a change in the current. Analyzing the exact nature               
of this change allows the identification of the template sequence. By adding a hairpin sequence               
to the end of the double-stranded cDNA fragment before denaturing it into a single-stranded              
molecule and passing it through the nanopore, both the template sequence and its complement              
are included in a single read and can be combined at the base-calling step to generate a                 
higher-quality, so called 2D, read ​[215]​. In contrast to PacBio, ONT also offers direct              
sequencing of RNA ​[216]​. Advantages of this include that the reverse transcription step is              
avoided, which may reduce biases, and that RNA modifications can be directly observed, since              
they also change the current passing through the nanopore in characteristic ways ​[217]​.             
However, at present, the required amount of starting material is considerably higher than for              
cDNA protocols. 
 
 
 Applications to cDNA (RNA) include both transcriptome-wide sequencing and characterization          
of specific genes via targeted sequencing ​[15,203,218–222]​, as well as performance           
evaluations based on synthetic transcript catalogs (ERCC with 92 sequences, or SIRV, with 68).              
Long-read transcript sequencing (LRTS) offers the potential that every read represents a            
full-length transcript. If this was indeed true, ​de novo (reference-free) identification of the full set               
of observed isoforms would be straightforward, and only require grouping together reads            
expected to differ only by sequencing errors (which, depending on the error rate and isoform               
similarity, may of course still not be trivial). This is, however, not currently the case, both due to                  
fragmentation and degradation of template molecules during library preparation and because of            
early termination of the sequencing, which leads to ambiguities in transcript identification ​[223]​.             
In particular, this means that it is not easy to determine whether truncated variants are present.  
 
Transcript identification from LRTS can be either reference-based or reference-free. The latter            
typically involves clustering reads based on similarity, followed by polishing of the consensus             
sequence within each cluster ​[15,224–227]​. Since LRTS is still a young field, methods and tools               
for reference-based alignment are still emerging, but so far include a mix of established tools,               
such as GMAP ​[58] and new innovations, such as minimap2 ​[228]​. A recent study comparing               
PacBio, ONT and Illumina data ​[203]​, showed that the long-read technologies were indeed             
much better at correctly identifying expressed SIRV transcripts than ​de novo assembly of short              
reads. 
 
The rapid technological developments in LRTS also mean that the read generation process,             
e.g., biases affecting the ability of observing a given read, is still largely unknown. In addition,                
read lengths are extremely variable, error rates are relatively high, and throughput is still              
relatively low. In particular for the PacBio RSII instrument, the selection of transcript molecules              
is biased towards short sequences ​[223]​. Thus, samples are typically size-fractionated before            
sequencing, which distorts the abundance estimates. Taken together, these and other aspects            
make accurate transcript quantification from LRTS more difficult, and new models and tools will              
be needed. Encouragingly, a recent study showed that by combining LRTS and Illumina data,              
more accurate quantifications for the artificial SIRV transcripts could be achieved ​[203]​. 
 
Since abundance estimation for long reads returns values in the form of read (or transcript)               
counts, it is plausible that the DE machinery developed for short-read data can be applied in a                 
similar way. The quality of the DE calls will be directly dependent on the accuracy of the                 
abundance estimates. However, the current low depth of sequencing compared to short-read            
data sets will ultimately lead to low power to detect DE features.  
Summary 
“I'm a scientist and I know what constitutes proof. But the reason I call myself by my childhood                  
name is to remind myself that a scientist must also be absolutely like a child. If [they] see a                   
thing, [they] must say that [they] see it, whether it was what [they] thought [they] were going to                  
 
 see or not. See first, think later, then test. But always see first. Otherwise you will only see what                   
you were expecting. Most scientists forget that.”  
― ​adapted from​ ​The Ultimate Hitchhiker's Guide to the Galaxy ​by Douglas Adams   
 
In this review, we gave an overview of the data science of gene expression analysis, with a                 
focus on methods to estimate transcript-level abundance and statistical tools for assessing DE.             
Notably, RNA-seq data is often an intermediate discovery step where the detected molecular             
changes represent candidates for further follow up. Nonetheless, the analysis of RNA-seq data             
for gene expression is already very mature, due to a deep understanding of the biases present,                
to the implementation of efficient data structures and algorithms for processing the data into              
(estimated) count tables and to a refined understanding of how well tools perform via the many                
benchmarks available. 
 
Ultimately, the success of RNA-seq lies in its wide range of applications and it is likely that                 
Illumina-based short-fragment RNA-seq will continue to be the workhorse for the field for many              
years. With increasing fidelity of single-cell protocols, many tools are emerging to deal with the               
additional complexities of single cell measurements and these will be further refined in the              
coming years. Similarly, with the decreasing costs and lower error rates of long-read             
technologies, it may be possible to characterize alternative transcription quantitatively with           
full-length transcript sequencing, thus considerably reducing read-to-transcript ambiguity;        
however, much still needs to be learned about the biases present. 
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